Actuate director granted 15,000 stock options
ACTUATE THERAPEUTICS, INC. director and 10% owner Todd S. Thomson received a grant of stock options covering 15,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ACTUATE THERAPEUTICS, INC. director and 10% owner Todd S. Thomson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, vest in full on the one-year anniversary of the grant date, and expire on May 21, 2036. Certain funds managed by Kairos Venture Investments, LLC are entitled to an indirect economic interest in these options because Thomson serves on the board as their representative.
Insider Trade Summary
Grant/Award: 15,000 shares
Grant/Award
1 txn
Insider
THOMSON TODD S
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 15,000 contracts (Direct)
Footnotes (2)
- F1. Options will vest in full on the anniversary of the grant date.
- F2. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.
Key Figures
Stock options granted: 15,000 options
Exercise price: $2.4200 per share
Underlying shares: 15,000 shares
+2 more
5 metrics
Stock options granted
15,000 options
Grant to Todd S. Thomson on May 21, 2026
Exercise price
$2.4200 per share
Strike price for 15,000 stock options
Underlying shares
15,000 shares
Common stock underlying the granted options
Total options after grant
15,000 options
Total derivative securities following the reported transaction
Expiration date
May 21, 2036
Option expiration for the 15,000-stock-option grant
Key Terms
Stock Options, grant/award acquisition, exercise price, pecuniary interest, +1 more
5 terms
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
exercise price financial
"conversion_or_exercise_price: "2.4200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
pecuniary interest financial
"entitled to an indirect pecuniary interest in such securities"
Kairos Venture Investments, LLC financial
"serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ACTU (Actuate Therapeutics) report in this Form 4?
Actuate Therapeutics reported that director and 10% owner Todd S. Thomson received a grant of 15,000 stock options. These options relate to common stock and were awarded as a compensation-related acquisition, not an open-market purchase or sale.
What are the key terms of Todd Thomson’s 15,000 ACTU stock options?
Todd Thomson’s grant covers 15,000 stock options with an exercise price of $2.4200 per share. The options vest in full on the anniversary of the grant date and expire on May 21, 2036, giving a long exercise window.
Does this ACTU Form 4 reflect a stock purchase or sale by Todd Thomson?
No, the Form 4 reflects a grant or award acquisition of 15,000 stock options to Todd Thomson. It is coded as an “A” transaction, meaning a compensation-related award rather than an open-market buy or sell of ACTU common shares.
How many ACTU derivative securities does Todd Thomson hold after this transaction?
Following this transaction, Todd Thomson holds 15,000 stock options as reported in the filing. These options are derivative securities linked to an equal number of underlying common shares, all reflecting direct ownership according to the Form 4 details.
What role does Kairos Venture Investments have in Todd Thomson’s ACTU options?
Footnotes state that Todd Thomson serves as CFO/COO of Kairos Venture Investments and represents Kairos-managed funds on Actuate’s board. Certain Kairos funds have a right to an indirect pecuniary interest in securities granted to him, including these stock options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
